Abstract
The prostacyclin receptor (IP - International Union of Pharmacology nomenclature) is a member of the seven transmembrane G-protein coupled receptor (GPCR) superfamily. Recent concerns with selective and non-selective COX-1/COX-2 inhibition have exposed an important cardioprotective role for IP in preventing atherothrombosis. Receptor dysfunction (genetic variants) or reduced signaling (COX-2 inhibition) in high cardiovascular risk patients leads to increased cardiovascular events. These clinical observations have also been confirmed genetically by mouse knockout studies. Thus, receptor regulation is paramount in ensuring correct function in the prevention of atherothrombosis. This review summarizes recent literature on how this important receptor is regulated, from transcription to transport (to and from the membrane surface). These regulatory processes are critical in ensuring that IP receptors are adequately expressed and functional on the cell surface.
Keywords: Prostacyclin receptor, activation, desensitization, dimerization, internalization, transcriptional regulation, homeostasis, hemostasis, atherothrombosis, atherosclerosis, inflammatory disease, coronary syndrome, stroke, platelets, restenotic lesions
Current Molecular Medicine
Title: Prostacyclin Receptor Regulation --- from Transcription to Trafficking
Volume: 11 Issue: 7
Author(s): C. Midgett, J. Stitham, K.A. Martin and J. Hwa
Affiliation:
Keywords: Prostacyclin receptor, activation, desensitization, dimerization, internalization, transcriptional regulation, homeostasis, hemostasis, atherothrombosis, atherosclerosis, inflammatory disease, coronary syndrome, stroke, platelets, restenotic lesions
Abstract: The prostacyclin receptor (IP - International Union of Pharmacology nomenclature) is a member of the seven transmembrane G-protein coupled receptor (GPCR) superfamily. Recent concerns with selective and non-selective COX-1/COX-2 inhibition have exposed an important cardioprotective role for IP in preventing atherothrombosis. Receptor dysfunction (genetic variants) or reduced signaling (COX-2 inhibition) in high cardiovascular risk patients leads to increased cardiovascular events. These clinical observations have also been confirmed genetically by mouse knockout studies. Thus, receptor regulation is paramount in ensuring correct function in the prevention of atherothrombosis. This review summarizes recent literature on how this important receptor is regulated, from transcription to transport (to and from the membrane surface). These regulatory processes are critical in ensuring that IP receptors are adequately expressed and functional on the cell surface.
Export Options
About this article
Cite this article as:
Midgett C., Stitham J., Martin K.A. and Hwa J., Prostacyclin Receptor Regulation --- from Transcription to Trafficking, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615144
DOI https://dx.doi.org/10.2174/156652411800615144 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inorganic Nanoparticles for In Vitro Cancer Diagnosis: A Patent Review
Recent Patents on Nanomedicine Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets New Trends in Anti-Atherosclerotic Agents
Current Medicinal Chemistry Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Endothelial Activation. Sliding Door to Atherosclerosis
Current Pharmaceutical Design Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Anti-Platelet Treatment of Middle-Sized Abdominal Aortic Aneurysms
Current Vascular Pharmacology Pollen Diversity, Antiradical and Antibacterial Activity and Phenolic Contents of some Polish Honeys
Current Nutrition & Food Science Vascular effects of flavonoids
Current Medicinal Chemistry Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Cardiovascular & Hematological Disorders-Drug Targets Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
Current Cardiology Reviews